Recombinant MS4A1 (Rituximab Biosimilar) anticorps
-
- Antigène Tous les produits MS4A1 (Rituximab Biosimilar)
- MS4A1 (Rituximab Biosimilar)
- Type d'anticorp
- Recombinant Antibody
-
Reactivité
- Humain
-
Hôte
-
Mammalian Cells
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp MS4A1 (Rituximab Biosimilar) est non-conjugé
-
Application
- ELISA
- Fonction
- Rituximab Biosimilar - Anti-MS4A1 mAb
- Attributs du produit
- Antibody Type: IgG1
- Classe de qualité
- Research Grade
- Isotype
- IgG1
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Stock
- 4 °C,-20 °C
- Stockage commentaire
- 4°C for short term, -20°C for long term
-
- Antigène
- MS4A1 (Rituximab Biosimilar)
- Abstract
- MS4A1 (Rituximab Biosimilar) Produits
- Synonymes
- anticorps B1, anticorps Bp35, anticorps CD20, anticorps CVID5, anticorps LEU-16, anticorps MS4A2, anticorps S7, anticorps membrane spanning 4-domains A1, anticorps MS4A1
- Classe de substances
- Biosimilar
- Sujet
-
Rituximab
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death. Rituximab is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and EpsteinBarr virus-positive mucocutaneous ulcers.
-